0001493152-26-016954
SEC filingThe company significantly narrowed its operating and net losses by approximately 65% and 74% respectively, driven by reduced operating expenses and the absence of prior-year non-recurring charges. However, minimal revenue and ongoing cash burn highlight continued execution risk as the company transitions to commercialization.
Loss from operations improved from -$36.5 million in the prior year to -$12.6 million in fiscal 2025, a reduction of approximately 65%. This improvement was driven by both reduced operating expenses and the absence of certain non-recurring charges recognized in the prior year. Specifically, the decrease in research and development expenses was primarily due to the sponsorship agreement with Korea University no longer being active and a decrease in stock compensation expense. These cost discipline measures demonstrate management's efforts to align the cost structure with the company's early-stage revenue profile.
Revenue increased 176% year-over-year to $275,120, though this remains immaterial in the context of the company's operating expenses. The growth reflects the company's transition from a pre-revenue development stage to early commercialization, with deployments and pilot initiatives across healthcare, hospitality, insurance, and media verticals. The company has established strategic partnerships with organizations such as SKYE LATAM, Valio Technologies, and Swiss Life Global Solutions to extend its market reach. Management believes these tools will empower businesses to elevate customer experiences, optimize cost management and supercharge operational efficiency. The company's "land and expand" strategy aims to convert initial deployments into broader, recurring revenue streams, but this remains unproven at scale.
Net cash provided by operating activities was -$5.1 million, an improvement from -$14.0 million in the prior year. This improvement was partially driven by a net cash inflow from changes in operating assets and liabilities, primarily due to an increase in accounts payable, partially offset by a decrease in accrued expenses. The company's principal source of liquidity as of December 31, 2025, was minimal. Management has indicated that the company will need to raise additional capital through equity or debt investments to fund ongoing operations. The company continues to evaluate the probability of warrant exercise and the merit of including potential cash proceeds in liquidity planning.
Diluted EPS was -$1.97 compared to -$1.02 in the prior year. The unfavorable per-share movement occurred despite the significant reduction in net loss, indicating a substantial decrease in the weighted average share count. This change reflects the impact of a 1-for-10 reverse stock split executed during the period, which proportionally reduced shares outstanding and magnified the per-share loss figure.
Looking ahead, management has explicitly stated that operating expenses are expected to increase substantially as the company enhances its offerings, expands its customer base, and continues technology development. The company's growth strategy depends on its ability to raise additional capital, and management has indicated it intends to pursue equity or debt investments. Investors should monitor the company's ability to secure additional financing and convert its strategic partnerships into sustainable revenue streams.